July 14, 2011 ·
Leave a comment
Industry Insights from Paul Meade, M. Sc, MPH
A recent article in the Wall Street Journal announced that Pfizer is conducting a clinical trial in which patients are able to use their computers and smartphones to enter information about the study, rather then spend time visiting a clinic. It was only a matter of time before clinical trials entered the social media era!
Actually, this approach makes a lot of sense, not just for the investigator, but especially for the patient. The patient is recruited over the Internet, enrolls electronically, receives laboratory tests in the mail along with test drugs, and tracks responses through an application on his or her computer or smartphone. Having participated in a clinical study before where I had to repeatedly return to the clinic, keep a paper log of reactions, bring in my responses to the study site, and answer weekly phone calls from the study nurse, I can say wholeheartedly that it was a big inconvenience. And all of that grief for the incredible reimbursement of $60!
We live in an age of instant and ubiquitous communication. I am never very far or long away from a business-related e-mail, even when I am on vacation. In fact, this instant communication has really changed the face of vacations for most people, but that is another subject ... read more »
TAGS: 
biopharmaceutical biotechnology clinical investigators clinical studies clinical study nurse clinical study site clinical trial computers e-visits family physicians Food and Drug Administration healthcare management healthcare system laboratory tests patient recruitment patients Pfizer pharmaceutical physicians smartphones social media Wall Street Journal
August 2, 2010 ·
2 comments
Key opinion leaders (KOLs) are health care leaders who make a high-impact footprint while advancing medical science. Thought Leader Select specializes in delivering objective, validated data on the skills and experiences of KOLs, so that pharmaceutical companies can seek their advice and guidance in the development of new medicines.
Over the past several years, Thought Leader Select has studied physician key opinion leaders who treat diabetes and analyzed their involvement in many areas, including clinical research, treatment guidelines involvement, publishing, reimbursement involvement and participation in advocacy efforts. In a recent assessment of nearly 500 diabetes KOLs across the United States, Thought Leader Select examined their participation in patient advocacy activities. Using keywords to link these KOLs with such activities, Thought Leader Select found that 62% of physicians regularly take part in patient advocacy efforts, such as participation in advocacy organizations, patient education or legislative efforts (see Chart 1).
Of the 301 KOLs with advocacy involvement, most take part in five or fewer activities, while only 3% of them boast 10 or more advocacy activities and/or awards. In addition to activities through the American Diabetes Association (ADA) and American Association of Clinical Endocrinologists (AACE) – especially the American College of Endocrinology’s Power of Prevention (POP) program – top advocacy initiatives and organizations include:
• Taking ... read more »
TAGS: 3163 AACE ACE ADA American Association of Clinical Endocrinologists American College of Endocrinology American Diabetes Association biopharmaceutical biotechnology Centers for Medicare and Medicaid Services CMS diabetes Diabetes Action Research and Education Foundation diabetes camp Diabetes Self Management FDA Food and Drug Administration health care health coverage health legislation healthcare key opinion leaders patient advocacy patient education pharmaceutical physicians POP Power of Prevention Specter Amendment state diabetes plan Taking Control of Your Diabetes TCOYD thought leaders United States
June 1, 2010 ·
Leave a comment
In a recent post on Pharmalot, the pharmaceutical industry blog highlighted a recent survey that gauged American opinions on the speed and safety of the process for developing new medicines. The survey, conducted by Eli Lilly and ResearchAmerica, measured a number of opinions Americans hold regarding the pharmaceutical industry and the FDA itself.
While over 70 per cent of the respondents trust the FDA approval process for new drugs, more than half say the process should be faster. The most stunning numbers in the survey come from the questions regarding industry collaborations with universities and the government. Ninety-four per cent of the respondents said that pharmaceutical companies, universities, and the government should work together to develop new medicines more quickly and safely, and 88 per cent said that it was a good idea for drug companies to collaborate with hospitals, universities, and other health institutions.
The Lilly/Research America survey gives even more weight, the weight of public opinion,that the pharmaceutical industry must continue to increase its collaborations with medical experts to ensure that new medicines are delivered safely and in a timely fashion. Working with the right experts at the right points of development can save millions of dollars in development costs, and, more importantly, save more lives.
At Thought Leader Select, the collaborative synergy of the pharmaceutical industry and medical experts ... read more »
TAGS: Americans clinical research clinical trials drug development drug discovery Eli Lilly ethics FDA Food and Drug Administration government agencies health survey key opinion leaders KOL engagement KOL identification KOL profiling KOLs medical researchers nurse practitioners Pharmalot physician assistants physicians regulatory/reimbursement specialists ResearchAmerica researchers Thought Leader Select thought leaders transparcency
